iCAD’s Xoft Intraoperative Radiation Therapy System Featured at American Society of Breast Surgeons Conference
NASHUA, N.H. & CHICAGO--(BUSINESS WIRE)--May 3, 2013--Booth #303 -- iCAD, Inc. (Nasdaq: ICAD), a leading provider of advanced imaging and radiation therapy technologies for the detection and treatment of cancer, today announced that the Company’s Xoft ® Axxent ® Electronic Brachytherapy System ® for Intraoperative Radiation Therapy (IORT) will be a featured subject of several scientific and training sessions at the American Society of Breast Surgeons’ 14 th Annual Meeting taking place this week at the Sheraton Chicago Hotel & Towers.
“We are pleased to have our Xoft System for the treatment of early-stage breast cancer so prominently featured before an audience of more than 1,000 of the world’s top breast surgeons at this premiere medical conference,” said Ken Ferry, President and CEO of iCAD. “The data presented further confirm the benefits of this therapy, and we look forward to new and continued opportunities to advance the treatment of breast cancer and improve the lives of patients.” IORT data and innovations will be discussed in the following poster and educational session: “Intra-Operative Radiation Therapy for Treatment of Early Stage Breast Cancer: Short Term Results from a Single Institution Clinical Trial Using Electronic Brachytherapy with a Disposable Balloon Applicator” The poster (#56) will be available for viewing as of 9:30 a.m. CT on Friday, May 3 Chicago Room 8-10, Level IV, Row J. Barbara S. Schwartzberg, MD, Rose Medical Center, Denver, Colo., will review the results of a 51-patient trial of the Xoft ® Axxent ® Electronic Brachytherapy System ®, finding no recurrences of breast cancer at an average of 14 months post-treatment from 6:00 p.m.-7:30 p.m. CT on Friday evening at the poster location. “Innovations and Advances in Breast Cancer Diagnosis and Treatment” Friday, May 3, 4:00 p.m.-5:30 p.m. CT Sheraton Chicago 4–7, Level IV The IORT portion of the General Session discussion will be led by Darius S. Francescatti, MD, JD, FACS, Assistant Professor, Rush Presbyterian St. Luke’s Medical Center, Chicago, Ill. “IORT is a significant advancement in the treatment of breast cancer, offering women a less burdensome option to traditional radiation therapy and mitigating the arduous road to recovery many of these patients face,” said Dr. Schwartzberg. “The data presented today show positive outcomes with no recurrence of cancer, further validating the efficacy of IORT for women with early-stage breast cancer.” About Xoft ® Axxent ® Electronic Brachytherapy System ® The Xoft System is an isotope-free radiation treatment cleared by the U.S. Food and Drug Administration and CE marked for use anywhere in the body, including for the treatment of early-stage breast cancer, endometrial cancer, cervical cancer and skin cancer. It utilizes a proprietary miniaturized x-ray as the radiation source that delivers precise treatment directly to cancerous areas while sparing healthy tissue and organs. A post-market study is underway to assess the safety and efficacy of Intraoperative Radiation Therapy with the Xoft System. Xoft, Inc. is a wholly owned subsidiary of iCAD, Inc. For more information about Xoft visit www.xoftinc.com.
About iCAD, Inc.
iCAD is a leading provider of advanced image analysis, workflow solutions and radiation therapies for the early identification and treatment of common cancers. iCAD offers a comprehensive range of high-performance, upgradeable CAD solutions for mammography and advanced image analysis and workflow solutions for Magnetic Resonance Imaging, for breast and prostate cancers and Computed Tomography for colorectal cancer. iCAD’s Xoft System, offers radiation treatment for early-stage breast cancer that can be administered in the form of Intraoperative Radiation Therapy or accelerated partial breast irradiation. The Xoft System is also cleared for the treatment of non-melanoma skin cancer, endometrial and cervical cancers. For more information, call 877-iCADnow, or visit www.icadmed.com.